Cipla wins $188.95 million of Global Fund ARV Tender

13 Feb 2015 Evaluate

Cipla has been awarded $188.95 million of Global Fund ARV Tender. The company has been selected as a ‘Panel Supplier’ for a Supplier Partnership Agreement. The contract is effective from the first of January 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.

The company has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs. The anti-retrovirals drugs will be manufactured in Cipla’s state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

 

Cipla Share Price

1424.40 4.85 (0.34%)
03-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1508.40
Dr. Reddys Lab 6332.85
Cipla 1424.40
Zydus Lifesciences 992.00
Lupin 1663.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.